Patent application number | Description | Published |
20090218714 | APPARATUS - The invention relates to apparatus for filling a cavity during production of a pharmaceutical dosage form. The apparatus comprises a cavity open at an upper surface and closed at a lower surface. The lower surface is defined by an initial layer of powder. A powder source and a fluid pump are also provided. The fluid pump is arranged to draw gas away from the cavity such that the gas pressure within the cavity is reduced below the ambient gas pressure before the cavity is filled to a predetermined fill level with powder from the powder source. | 09-03-2009 |
20100003321 | SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME - Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made. | 01-07-2010 |
20100035949 | MICROEMULSION DOSAGE FORMS OF VALSARTAN AND METHODS OF MAKING THE SAME - A drug delivery system, e.g., microemulsion preconcentrate, that spontaneously forms a microemulsion when brought in contact with an aqueous medium. The drug delivery system contains valsartan, a hydrophilic component, a lipophilic component and a surfactant. A particularly useful hydrophilic component in the system is a polymer that is solid at room temperature, e.g., solid PEG. | 02-11-2010 |
20100303906 | SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME - Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made. | 12-02-2010 |
20120164218 | SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME - Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made. | 06-28-2012 |
20120177733 | SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME - Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made. | 07-12-2012 |
20130245061 | PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing; processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions for administration thereof; and related uses and methods of treatment. | 09-19-2013 |
20140094522 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS - Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided. | 04-03-2014 |
20140309250 | Pharmaceutical Formulations - This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of the formulations for treating proliferative diseases, such as solid tumor diseases. | 10-16-2014 |